Castle Peak Hospital, Hong Kong, China; Department of Psychiatry, The University of Hong Kong, Hong Kong Special Administrative Region, China.
Castle Peak Hospital, Hong Kong, China.
J Psychiatr Res. 2021 Jun;138:607-614. doi: 10.1016/j.jpsychires.2021.05.018. Epub 2021 May 8.
Schizophrenia patients exhibit subtle and non-localizing neurological abnormalities, known as neurological soft signs (NSS). Life-span evidence suggests that NSS vary along the course of schizophrenia. An association between NSS and treatment response has been proposed, suggesting that NSS reflect the underlying neuropathology development in schizophrenia. However, few studies have investigated the relationship between NSS and treatment resistance in first-episode schizophrenia patients. We conducted a longitudinal study on 52 first-episode schizophrenia patients, who were assessed at baseline, the sixth month, and the fifth year using the abridged version of the Cambridge Neurological Inventory. The trajectories of NSS between 29 treatment-responsive patients (with full symptomatic remission) and 23 treatment-resistant patients (who received clozapine) were compared using mixed model ANOVA. We also controlled for the effect of age and estimated IQ, using a mixed ANCOVA model. Although the two schizophrenia groups had comparable NSS at the baseline, their trajectories of NSS differed significantly. Compared with their treatment-responsive counterparts, treatment-resistant schizophrenia patients had worsening of NSS over time. Our findings support the potential utility of NSS in identifying treatment resistance in first-episode schizophrenia. Progressive worsening of NSS in treatment-resistant schizophrenia patients may reflect the development of underlying neuropathology. Further studies using large samples of treatment-resistant schizophrenia patients are needed.
精神分裂症患者表现出微妙且非定位的神经异常,称为神经学软性体征 (NSS)。 生命周期的证据表明,NSS 在精神分裂症的病程中会发生变化。 有人提出 NSS 与治疗反应之间存在关联,表明 NSS 反映了精神分裂症中潜在的神经病理学发展。 然而,很少有研究调查 NSS 与首发精神分裂症患者的治疗抵抗之间的关系。 我们对 52 名首发精神分裂症患者进行了一项纵向研究,这些患者在基线、第六个月和第五年使用剑桥神经学检查量表的简表进行了评估。 使用混合模型 ANOVA 比较了 29 名治疗反应良好的患者(症状完全缓解)和 23 名治疗抵抗的患者(接受氯氮平治疗)之间的 NSS 轨迹。 我们还使用混合 ANCOVA 模型控制了年龄和估计智商的影响。 尽管两组精神分裂症患者在基线时的 NSS 相似,但他们的 NSS 轨迹存在显著差异。 与治疗反应良好的患者相比,治疗抵抗的精神分裂症患者的 NSS 随着时间的推移逐渐恶化。 我们的研究结果支持 NSS 在识别首发精神分裂症患者治疗抵抗方面的潜在作用。 治疗抵抗的精神分裂症患者的 NSS 逐渐恶化可能反映了潜在神经病理学的发展。 需要使用更大样本量的治疗抵抗的精神分裂症患者进行进一步研究。